Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | PDK2 | Q15119 | 7/20 | 0.50 |
| ▸ | MEN1 | O00255 | 2/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.50 |
| ▸ | CCNC | P24863 | 1/20 | 0.48 |
| ▸ | CDK8 | P49336 | 1/20 | 0.48 |
| ▸ | NPC1 | O15118 | 3/20 | 0.44 |
| ▸ | RAB9A | P51151 | 3/20 | 0.44 |
| ▸ | LTA4H | P09960 | 1/20 | 0.43 |
| ▸ | PTGS2 | P35354 | 1/20 | 0.43 |
| ▸ | CTSS | P25774 | 1/20 | 0.42 |
| ▸ | HPGDS | O60760 | 1/20 | 0.41 |
| ▸ | RET | P07949 | 1/20 | 0.41 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.40 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29744050 | 1.00 | POLB (0.53) | POLBPDK2MEN1KMT2ACCNC | |
| SCHEMBL23405958 | 0.96 | POLB (0.49) | POLBPDK2MEN1KMT2ACCNC | |
| SCHEMBL29744046 | 0.96 | POLB (0.49) | POLBPDK2MEN1KMT2ACCNC | |
| SCHEMBL23405937 | 0.89 | POLB (0.57) | POLBPDK2MEN1KMT2ACCNC | |
| SCHEMBL29743908 | 0.89 | POLB (0.57) | POLBPDK2MEN1KMT2ACCNC | |
| SCHEMBL23406112 | 0.86 | POLB (0.53) | POLBPDK2MEN1KMT2ACCNC | |
| SCHEMBL29743914 | 0.86 | POLB (0.53) | POLBPDK2MEN1KMT2ACCNC | |
| SCHEMBL23406022 | 0.85 | MEN1 (0.49) | POLBPDK2MEN1KMT2ACCNC | |
| SCHEMBL29743996 | 0.85 | MEN1 (0.49) | POLBPDK2MEN1KMT2ACCNC | |
| SCHEMBL19153568 | 0.82 | MEN1 (0.52) | POLBPDK2MEN1KMT2ACCNC |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11377436-B2 | EAAT2 enhancing molecules | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-11377436-B2 | EAAT2 enhancing molecules | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2022-07-05 | — | — | US | disclosed |
| US-20210163440-A1 | EAAT2 ENHANCING MOLECULES | BRIGHAM & WOMENS HOSPITAL INC (US) | 2021-06-03 | — | — | US | disclosed |
| US-20210163440-A1 | EAAT2 ENHANCING MOLECULES | BRIGHAM & WOMENS HOSPITAL INC (US) | 2021-06-03 | — | — | US | disclosed |
| WO-2019014460-A1 | EAAT2 ENHANCING MOLECULES | THE BRIGHAM AND WOMEN'S HOSPITAL, INC. (US) | 2019-01-17 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210163440-A1 | EAAT2 ENHANCING MOLECULES | SLC1A2, SLC1A1, SLC1A3 | POLB 3237/4885PDK2 237/4885MEN1 4867/4885 |
| US-11377436-B2 | EAAT2 enhancing molecules | SLC1A2, SLC1A1, SLC1A3 | POLB 3237/4885PDK2 237/4885MEN1 4867/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.